The World Health Organization will soon be examining the feedback drawn by its revised target product profile (TPP) for human vaccines for mpox, which specifies that the preferred efficacy of new vaccines should ideally be greater than 90%, with a minimum acceptable efficacy of over 60%.
Stakeholders had until 23 August to comment on the updated draft TPP, which is intended for vaccine scientists, product developers,...







